Erdafitinib improves overall survival in FGFR3-altered urothelial carcinoma with HR 0.64 compared to chemotherapy
Trial shows erdafitinib improves survival for specific bladder cancers
In a randomized controlled trial of 266 patients with locally advanced or metastatic urothelial carcinoma and susceptible FGFR3 alterations,…
A new treatment called erdafitinib showed improved survival for patients with specific genetic markers in advanced urothelial carcinoma.
Single 6 mg erdafitinib dose shows similar pharmacokinetics in mild or moderate hepatic impairment versus healthy controls
Single dose of erdafitinib showed no dose changes needed for mild or moderate liver issues
This Phase 1 open-label single-dose study evaluated pharmacokinetics of erdafitinib in 26 participants with hepatic impairment versus health…
A single dose of erdafitinib worked well in people with mild or moderate liver problems, showing no need for dose adjustments.